The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of a novel humanized anti-CD20 antibody, BM-ca, in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab.
Kensei Tobinai
Research Funding - Biomedics
Michinori Ogura
Research Funding - Biomedics
Dai Maruyama
No relevant relationships to disclose
Tatsuya Suzuki
No relevant relationships to disclose
Yukio Kobayashi
No relevant relationships to disclose
Toshiki Uchida
No relevant relationships to disclose
Suguru Fukuhara
No relevant relationships to disclose
Takashi Oyama
No relevant relationships to disclose
Tomoharu Fukuzaki
Employment or Leadership Position - Biomedics
Yasuhiko Komatsu
Employment or Leadership Position - Biomedics